Catalyst Dossier · compiled by CeliA 🧫

Sandoz Group AG (SDZ.SW)

Pharmaceutical Preparations · market cap $34.2B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Sandoz Group AG (SDZ.SW) is a large-cap generics and biosimilars-focused pharmaceutical company with 22,356 employees and a market cap of approximately $34.2B. The company operates a broad pipeline of biosimilar and generic candidates across multiple Phase 3 programs, with the most proximate binary catalyst being a Phase 3 readout for CYB704 in Relapsing Multiple Sclerosis expected around November 15, 2026. Sandoz is not a pure-play clinical-stage biotech but rather an established commercial-scale generics/biosimilars operator with late-stage pipeline optionality.

The catalyst path

2026-11-15 (est.)Phase 3 · CYB704imp 9/10

Pipeline

Asset	Phase	Indication
SOK583A1 (40 mg/mL)	Phase 3	Neovascular Age-related Macular Degeneration
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)	Phase 3	Rhinitis, Allergic, Seasonal
HX575 epoetin alfa (Sandoz)	Phase 3	Chronic Kidney Disease
HX575, solution for injection (s.c.)	Phase 3	Anemia
GP2015 Etanercept	Phase 3	Chronic Stable Plaque Psoriasis
GP2013	Phase 3	Follicular Lymphoma
HX575 epoetin alfa	Phase 3	Anemia
Broncho-munal®	Phase 3	Acute Uncomplicated Respiratory Tract Infections
GP2411	Phase 3	Postmenopausal Women With Osteoporosis
Neulasta®	Phase 3	Chemotherapy-induced Neutropenia
GP2015	Phase 3	Rheumatoid Arthritis
EP2006	Phase 3	Chemotherapy Associated Neutropenia
LRG-002	Phase 3	Antibiotic-associated Diarrhea
Adalimumab - GP2017	Phase 3	Rheumatoid Arthritis
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)	Phase 3	Rhinitis, Allergic, Seasonal
HX575 epoetin alfa Hexal AG	Phase 3	Anemia
MabThera	Phase 2	Rheumatoid Arthritis
acetylcysteine	Phase 3	Rhinosinusitis
LA-EP2006	Phase 3	Neutropenic Complications
SOK583A1	Phase 3	Neovascular Age-related Macular Degeneration (nAMD)

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SDZ.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.